Results 61 to 70 of about 5,801 (166)
Nature Communications, 2022 Molnupiravir was the first orally available SARS-CoV-2 antiviral approved for outpatient use against SARS-CoV-2, but its efficacy against variants of concern, especially delta, was questioned.
Carolin M. Lieber +14 more
doaj +1 more source
Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1604-1613, June 2026.Patients with severe renal impairment and COVID‐19 are at high risk for severe disease and death. Nirmatrelvir/ritonavir, an antiviral therapy for COVID‐19, is eliminated by renal excretion and can accumulate in patients with severe renal impairment.
Jacqueline Gerhart +7 more
wiley +1 more source
Unveiling the Power of Deuterium in Drug Discovery: A Comprehensive Overview
MedComm, Volume 7, Issue 6, June 2026.The role of deuterium replacement in drug discovery, its progress, opportunities, and challenges. ABSTRACT Deuterium, the heavy isotope of hydrogen, has unfolded as a cornerstone in modern drug discovery due to its potential to influence metabolic stability and pharmacokinetic behavior.
Mukta Lele +7 more
wiley +1 more source
Repurposed Medicines for Viruses With Epidemic or Pandemic Potential: A Horizon Scan
Pharmacology Research &Perspectives, Volume 14, Issue 3, June 2026.ABSTRACT Viruses such as Ebola, Marburg, influenza, mpox, MERS‐CoV, SARS‐CoV, and SARS‐CoV‐2 may be considered pathogens of epidemic or pandemic concern. Developing novel antiviral medicines can be time‐consuming and resource intensive. Repurposing existing medicines with known or potential antiviral activity offers a faster, cost‐effective strategy to
Sola Akinbolade +5 more
wiley +1 more source
ChemistrySelect, Volume 11, Issue 21, 4 June 2026.Tautomerization‐assisted oxidation of molnupiravir by superoxide (O2•−) in aprotic DMF. The thermodynamically favored oxime tautomer of the N4‐hydroxycytosine moiety forms a prereactive complex (PRC) with O2•− through hydrogen‐bonding interactions.
Tatsushi Nakayama, Kaisei Hara
wiley +1 more source
A Bayesian Analysis of the Molnupiravir Trial Data
, 2021 On October 1st 2021, Merck issued a press release claiming that "molnupiravir (MK-4482, EIDD-2801), an investigational oral antiviral medicine, significantly reduced the risk of hospitalization or death at a planned interim analysis of the Phase 3 MOVe-OUT trial in at risk, non-hospitalized adult patients with mild-to-moderate COVID-19." Specifically ...
Eric-Jan Wagenmakers +1 more
openaire +2 more sources
Veterinary Record Open, Volume 13, Issue 1, June 2026.Abstract Background Feline coronavirus (FCoV) causes inapparent to progressive fatal feline infectious peritonitis (FIP) in domestic and wild cats, which affects multiple‐organ systems. Methods We investigated three clinically sick cats using different laboratory and molecular tests to diagnose and confirm FCoV and propagate the virus in Vero cell ...
Eaftekhar Ahmed Rana +5 more
wiley +1 more source
Bioluminescence imaging reveals enhanced SARS-CoV-2 clearance in mice with combinatorial regimens
iScienceSummary: Direct acting antivirals (DAAs) represent critical tools for combating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) that have escaped vaccine-elicited spike-based immunity and future coronaviruses with ...
Irfan Ullah +13 more
doaj +1 more source
Molnupiravir: Mechanism of action, clinical, and translational science
Clinical and Translational ScienceMolnupiravir is an oral prodrug of the broadly active, antiviral ribonucleoside analog N‐hydroxycytidine (NHC). The primary circulating metabolite NHC is taken up into cells and phosphorylated to NHC‐triphosphate (NHC‐TP).
Brian M. Maas +9 more
doaj +1 more source